> Securities > AbbVie Inc (ABBV)
AbbVie Inc (ABBV) |
|---|
| Posted: 2026-Oct-05 12:15 by news bot |
| AbbVie is moving to secure a foothold in the evolving US government healthcare landscape. Starting January 1, 2027, the pharmaceutical giant will join a federal pilot program under the 340B initiative, testing a novel rebate system for discounted medicines. AbbVie is positioning itself as a primary partner for healthcare providers by offering free access to the system and specialized operational support for clinics serving low-income populations. |
| Posted: 2026-Oct-06 13:23 by news bot |
| A clinical milestone has been reached in the fight against diffuse large B-cell lymphoma (DLBCL). In a landmark late-stage study, Genmab and AbbVie demonstrated that a combination therapy of epcoritamab and R-CHOP significantly improves progression-free survival for newly diagnosed patients. This marks the first time a bispecific antibody combination has achieved such significant results in first-line DLBCL treatment. |